Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.41 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.38 |
| ▸ | TPH1 | P17752 | 2/20 | 0.38 |
| ▸ | TPH2 | Q8IWU9 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969564 | 1.00 | MME (0.69) | MMETAAR1ACEPPARGMMEL1 | |
| SCHEMBL19888579 | 0.92 | MME (0.59) | MMETAAR1ACEPPARGMMEL1 | |
| SCHEMBL11969895 | 0.87 | MME (0.52) | MMEACEPPARGGPR88EPHX2 | |
| SCHEMBL14919221 | 0.87 | MME (0.52) | MMEACEPPARGGPR88EPHX2 | |
| SCHEMBL18597892 | 0.82 | MME (0.48) | MMEPPARGCA12CA1CA2 | |
| SCHEMBL14890510 | 0.82 | MME (0.48) | MMEPPARGCA12CA1CA2 | |
| SCHEMBL12974571 | 0.82 | MME (0.52) | MMETAAR1ACEPPARGMMEL1 | |
| SCHEMBL14891213 | 0.82 | MME (0.73) | MMEACEMMEL1 | |
| SCHEMBL12684793 | 0.80 | MME (0.60) | MMETAAR1ACEMMEL1GPR34 | |
| SCHEMBL16939261 | 0.80 | MME (0.55) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9783507-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783507-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9593110-B2 | Neprilysin inhibitors | Theravence Biopharma R&D IP, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593110-B2 | Neprilysin inhibitors | Theravence Biopharma R&D IP, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005740-B2 | Neprilysin inhibitors | MME, REN, AGTR1 | MME 1/4885TAAR1 413/4885ACE 4/4885 |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885TAAR1 413/4885ACE 4/4885 |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885TAAR1 413/4885ACE 4/4885 |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885TAAR1 413/4885ACE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.